WO2004067002A3 - SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT - Google Patents
SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT Download PDFInfo
- Publication number
- WO2004067002A3 WO2004067002A3 PCT/EP2004/000951 EP2004000951W WO2004067002A3 WO 2004067002 A3 WO2004067002 A3 WO 2004067002A3 EP 2004000951 W EP2004000951 W EP 2004000951W WO 2004067002 A3 WO2004067002 A3 WO 2004067002A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- urinary tract
- lower urinary
- treatment
- selective
- neuromuscular dysfunction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04706676A EP1599204A2 (en) | 2003-01-30 | 2004-01-30 | Selective mglu5 antagonists for treatment of neuromuscular dysfunction of the lower urinary tract |
JP2006501708A JP2006516587A (en) | 2003-01-30 | 2004-01-30 | Selective mGlu5 antagonists for the treatment of neuromuscular disorders of the lower urinary tract |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000151A ITMI20030151A1 (en) | 2003-01-30 | 2003-01-30 | USE OF SELECTIVE MGLU5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROMUSCULAR DYSFUNCTIONS OF THE LOWER URINARY TRACT. |
ITMI2003A000151 | 2003-01-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004067002A2 WO2004067002A2 (en) | 2004-08-12 |
WO2004067002A3 true WO2004067002A3 (en) | 2004-11-25 |
Family
ID=32800691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/000951 WO2004067002A2 (en) | 2003-01-30 | 2004-01-30 | SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1599204A2 (en) |
JP (1) | JP2006516587A (en) |
IT (1) | ITMI20030151A1 (en) |
TW (1) | TW200418798A (en) |
WO (1) | WO2004067002A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691849B2 (en) | 2008-09-02 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
US8691813B2 (en) | 2008-11-28 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
US8697689B2 (en) | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
US8722894B2 (en) | 2007-09-14 | 2014-05-13 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
US8748621B2 (en) | 2007-09-14 | 2014-06-10 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
US8785486B2 (en) | 2007-11-14 | 2014-07-22 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US8841323B2 (en) | 2006-03-15 | 2014-09-23 | Janssen Pharmaceuticals, Inc. | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors |
US8906939B2 (en) | 2007-03-07 | 2014-12-09 | Janssen Pharmaceuticals, Inc. | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
US8937060B2 (en) | 2009-05-12 | 2015-01-20 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders |
US8946205B2 (en) | 2009-05-12 | 2015-02-03 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
US9012448B2 (en) | 2010-11-08 | 2015-04-21 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
US9085577B2 (en) | 2009-05-12 | 2015-07-21 | Janssen Pharmaceuticals, Inc. | 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US9114138B2 (en) | 2007-09-14 | 2015-08-25 | Janssen Pharmaceuticals, Inc. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones |
US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7531529B2 (en) | 2003-06-05 | 2009-05-12 | Roche Palo Alto Llc | Imidazole derivatives |
ATE445399T1 (en) | 2004-03-22 | 2009-10-15 | Lilly Co Eli | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS |
JP4690395B2 (en) | 2004-06-01 | 2011-06-01 | エフ.ホフマン−ラ ロシュ アーゲー | Pyridine-4-ethynyl-imidazole and pyrazole as mGlu5 receptor antagonists |
GB0514296D0 (en) * | 2005-07-12 | 2005-08-17 | Novartis Ag | Organic compounds |
WO2007054436A2 (en) | 2005-11-08 | 2007-05-18 | F. Hoffmann-La Roche Ag | Thiazolo [4 , 5-c] pyridine derivatives as mglu5 receptor antagonists |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
EP2178858B1 (en) | 2007-08-02 | 2011-12-28 | Recordati Ireland Limited | Novel heterocyclic compounds as mglu5 antagonists |
JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
DK3431106T3 (en) | 2014-01-21 | 2021-03-15 | Janssen Pharmaceutica Nv | COMBINATIONS INCLUDING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROP GLUTAMATERG SUBTYPE 2 RECEPTOR AND USE OF THESE |
ES2860298T3 (en) | 2014-01-21 | 2021-10-04 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use |
MY195177A (en) | 2015-06-23 | 2023-01-11 | Kissei Pharmaceutical | Pyrazole Derivative or Pharmaceutically Acceptable Salt Thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999002497A2 (en) * | 1997-07-11 | 1999-01-21 | Novartis Ag | Pyridine derivatives |
WO2002046166A1 (en) * | 2000-12-04 | 2002-06-13 | F. Hoffmann-La Roche Ag | Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
WO2002092086A1 (en) * | 2001-03-27 | 2002-11-21 | F. Hoffmann-La Roche Ag | Imidazo (1,2-a)-pyridine derivatives as mglur5 antagonists |
WO2002094795A1 (en) * | 2001-05-23 | 2002-11-28 | F. Hoffmann-La Roche Ag | 4-aminopyrimidine derivatives |
WO2003066595A2 (en) * | 2002-02-01 | 2003-08-14 | Euro-Celtique S.A. | 2 - piperazine - pyridines useful for treating pain |
WO2003093236A1 (en) * | 2002-05-02 | 2003-11-13 | Euro-Celtique, S.A. | 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor |
WO2004002983A2 (en) * | 2002-06-28 | 2004-01-08 | Euro-Celtique, S.A. | Therapeutic piperazine derivatives useful for treating pain |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9601680D0 (en) * | 1996-01-27 | 1996-03-27 | Pfizer Ltd | Therapeutic agents |
IT1293807B1 (en) * | 1997-08-01 | 1999-03-10 | Recordati Chem Pharm | 1- (N-PHENYLAMINOALKYL) PIPERAZINE DERIVATIVES SUBSTITUTED AT POSITION 2 OF THE PHENYL RING |
CN1308324C (en) * | 2000-08-31 | 2007-04-04 | 弗·哈夫曼-拉罗切有限公司 | Quinazoline derivatives as alpha-1 adrenergic antagonists |
-
2003
- 2003-01-30 IT IT000151A patent/ITMI20030151A1/en unknown
-
2004
- 2004-01-30 EP EP04706676A patent/EP1599204A2/en not_active Withdrawn
- 2004-01-30 JP JP2006501708A patent/JP2006516587A/en active Pending
- 2004-01-30 TW TW093102163A patent/TW200418798A/en unknown
- 2004-01-30 WO PCT/EP2004/000951 patent/WO2004067002A2/en active Search and Examination
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999002497A2 (en) * | 1997-07-11 | 1999-01-21 | Novartis Ag | Pyridine derivatives |
WO2002046166A1 (en) * | 2000-12-04 | 2002-06-13 | F. Hoffmann-La Roche Ag | Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
WO2002092086A1 (en) * | 2001-03-27 | 2002-11-21 | F. Hoffmann-La Roche Ag | Imidazo (1,2-a)-pyridine derivatives as mglur5 antagonists |
WO2002094795A1 (en) * | 2001-05-23 | 2002-11-28 | F. Hoffmann-La Roche Ag | 4-aminopyrimidine derivatives |
WO2003066595A2 (en) * | 2002-02-01 | 2003-08-14 | Euro-Celtique S.A. | 2 - piperazine - pyridines useful for treating pain |
WO2003093236A1 (en) * | 2002-05-02 | 2003-11-13 | Euro-Celtique, S.A. | 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor |
WO2004002983A2 (en) * | 2002-06-28 | 2004-01-08 | Euro-Celtique, S.A. | Therapeutic piperazine derivatives useful for treating pain |
Non-Patent Citations (1)
Title |
---|
TANAKA HIROSHI ET AL: "Effects of a selective metabotropic glutamate receptor agonist on the micturition reflex pathway in urethane-anesthetized rats.", NEUROUROLOGY AND URODYNAMICS, vol. 22, no. 6, 2003, pages 611 - 616, XP009032144, ISSN: 0733-2467 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841323B2 (en) | 2006-03-15 | 2014-09-23 | Janssen Pharmaceuticals, Inc. | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors |
US9266834B2 (en) | 2006-03-15 | 2016-02-23 | Janssen Pharmaceuticals, Inc. | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors |
US8906939B2 (en) | 2007-03-07 | 2014-12-09 | Janssen Pharmaceuticals, Inc. | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
US9114138B2 (en) | 2007-09-14 | 2015-08-25 | Janssen Pharmaceuticals, Inc. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones |
US8722894B2 (en) | 2007-09-14 | 2014-05-13 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
US8748621B2 (en) | 2007-09-14 | 2014-06-10 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones |
US9132122B2 (en) | 2007-09-14 | 2015-09-15 | Janssen Pharmaceuticals, Inc. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones |
US8785486B2 (en) | 2007-11-14 | 2014-07-22 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US8691849B2 (en) | 2008-09-02 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
US8697689B2 (en) | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
US8691813B2 (en) | 2008-11-28 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
US8937060B2 (en) | 2009-05-12 | 2015-01-20 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders |
US9085577B2 (en) | 2009-05-12 | 2015-07-21 | Janssen Pharmaceuticals, Inc. | 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US9226930B2 (en) | 2009-05-12 | 2016-01-05 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders |
US8946205B2 (en) | 2009-05-12 | 2015-02-03 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US9012448B2 (en) | 2010-11-08 | 2015-04-21 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
Also Published As
Publication number | Publication date |
---|---|
EP1599204A2 (en) | 2005-11-30 |
ITMI20030151A1 (en) | 2004-07-31 |
TW200418798A (en) | 2004-10-01 |
JP2006516587A (en) | 2006-07-06 |
WO2004067002A2 (en) | 2004-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004067002A3 (en) | SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT | |
WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
WO2005107726A3 (en) | Method for the treatment of back pain | |
WO2005011586A3 (en) | Treatment and preventi0n of cardiovascular events | |
WO2004113335A3 (en) | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents | |
WO2005079387A3 (en) | Implantable drug delivery device including wire filaments | |
WO2004000354A3 (en) | Method of treating the syndrome of lipodystrophy | |
WO2001076573A3 (en) | Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups | |
WO2005002515A3 (en) | Delivery of therapeutic compounds to the brain and other tissues | |
CA2363990A1 (en) | Use of glycyrrhizin in the treatment of mastitis | |
WO2001072291A3 (en) | Treatment of movement disorders with metabotropic glutamate receptor antagonist | |
WO2002100390A3 (en) | Improved method of treating the syndrome of coronary heart disease risk factors in humans | |
WO2003092580A3 (en) | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | |
WO2006044362A3 (en) | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | |
CA2498022A1 (en) | Combination of mglur antagonists for the treatment of addictive disorders | |
WO2005092009A3 (en) | Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders | |
WO2002099388A3 (en) | Benzodiazepine bradykinin antagonists | |
WO2004017896A3 (en) | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist | |
AU1423795A (en) | Treatment of normotensive glaucoma with angiotensin ii antagonists | |
WO2004110380A3 (en) | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents | |
WO2001001972A3 (en) | SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | |
WO2005042027A3 (en) | Antagonists of the bradykinin b1 receptor | |
EP1413201A3 (en) | Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals | |
WO2005107752A3 (en) | Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin | |
CA2338066A1 (en) | Treatment of dyskinesia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006501708 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004706676 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004706676 Country of ref document: EP |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) |